| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.2M | — | -4.6% |
| SG&A Expense | $1.7M | — | +32.0% |
| Operating Income | -$2.9M | — | -6.7% |
| Interest Expense | -$4K | — | +86.2% |
| Net Income | -$2.7M | — | +0.9% |
| EPS (Basic) | -$0.57 | — | +18.6% |
| EPS (Diluted) | -$0.57 | — | +18.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $9.5M | -28.7% | +194.5% |
| Current Assets | $10.0M | -27.6% | +180.0% |
| Total Assets | $10.4M | -27.1% | +143.2% |
| Current Liabilities | $7.3M | -44.1% | -39.9% |
| Stockholders' Equity | -$12.7M | +10.8% | +41.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.7M | — | -29.2% |
| Financing Cash Flow | -$2.1M | — | — |